BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home
»
Authors
»
Nuala Moran
Articles by Nuala Moran
Antisoma Planning Financing To Stay Ahead, Keep Flexibility
Feb. 14, 2001
By
Nuala Moran
Oxford Glyco Plans Gaucher NDA On Cerezyme Comparison Study
Feb. 14, 2001
By
Nuala Moran
Acambis Achieves Early Results That Validate Flavivirus Vaccine
Feb. 14, 2001
By
Nuala Moran
British Biotech's Marimistat Fails In Promising Indication
Feb. 14, 2001
By
Nuala Moran
Oxford Glyco Plans Gaucher NDA On Cerezyme Comparison Study
Feb. 14, 2001
By
Nuala Moran
Acambis Achieves Early Results That Validate Flavivirus Vaccine
Feb. 14, 2001
By
Nuala Moran
KS Biomedix Moves Lead Drug Into Phase IIb, Eyes Pivotal Trial
Feb. 14, 2001
By
Nuala Moran
Antisoma Planning Financing To Stay Ahead, Keep Flexibility
Feb. 14, 2001
By
Nuala Moran
British Biotech's Marimistat Fails In Promising Indication
Feb. 14, 2001
By
Nuala Moran
Protherics Gains U.S. Approval Of CroFab, Raises £3.1M Privately
Feb. 7, 2001
By
Nuala Moran
Previous
1
2
…
524
525
526
527
528
529
530
531
532
Next
